Angiogenesis based cancer therapy including anti-VEGFR-2 antibody, small molecules against VEGFR-2 signaling [6], [7], and VEGFR chimeric protein [8], has been proven to be an efficient strategy for treating of multiple cancer types. The gene discussed is KDR; the disease is cancer.